Search Results

CSL develops innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions.

https://www.csl.com/

Rights are allocated in two tranches and vesting occurs following the disclosure of half year and full year financial results following the grant of Rights.

https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2020-full.pdf

The financial results for each half year ended 31 December are generally reported in February each year.

https://www.csl.com/-/media/csl/documents/csl-governance-docs/communications-external-disclosure-policy.pdf

We announced our 2021 Half Year Financial Results on Thursday, 18th February 2021 (AEDT).

https://www.csl.com/investors/half-year-results-2021

We announced our 2021 Full Year Financial Results for the period ending 30th June 2021 on Wednesday, 18th August 2021 (AEST).

https://www.csl.com/investors/full-year-results-2021

In addition to delivering solid improve the efficiency of our business and the way in which financial results, we made significant contributions in the we help patients.

https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf

20th October 2020 Forward looking statements The information in this presentation is current as of the date of this presentation, and includes forward looking statements about CSL Limited and its related bodies corporate's (CSL) financial results and estimates, business prospects and product candidates in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.

https://medialib.csl.com/-/media/shared/documents/7/rd-investor-briefing-2020.pdf

You should read these Risk Factors along with our Annual Report for the fiscal year ending 30 June 2018 and the announcement of the Financial Results to 30 June 2018, available as described under "General Information— Documents Available for Inspection", which provide a more complete description of our business and any public announcements.

https://www.csl.com/-/media/csl/documents/february-2019-csl-prospectus_final.pdf

Commencing in 2017, publish an annual Tax Transparency Report (approved by the Board) that includes an explanation of taxes paid, why tax and financial results may vary and describes the operation of the tax governance framework

https://www.csl.com/-/media/csl/tax-transparency-reports/csl-limited-tax-transparency-report-2017.pdf

R&D Investor Briefing December 4, 2019 After struggling for years to get an accurate diagnosis, hereditary Legal Notice angioedema (HAE) patient Kathrin Schoen is working to ensure Forward looking statements the next generation of The materials in this presentation speak only as of the date of these materials, and include forward looking patients doesn't have statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, to wait so long. business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.

https://www.csl.com/-/media/shared/documents/7/rd-investor-briefing-2019.pdf